Susan M Wright

US Patent:

20030050248, Mar 13, 2003

Filed:

Feb 9, 2001

Appl. No.:

09/780967

Inventors:

Susan Wright - Saratoga CA, US
James Larrick - Woodside CA, US
Yuqiang Wang - Mountain View CA, US

International Classification:

A61K038/08
C07K007/06

US Classification:

514/017000, 530/329000

Abstract:

Isolated synthetic modified amino acids and peptides, which inhibit of the production of virulence factors in bacteria, particularly Staphylococcus, are described. The amino acids and peptides can be used in a method for treatment or prevention of Staphylococcal infections or can be integrated into a medical device to inhibit the development of infection associated with the use of such devices.

US Patent:

20030207933, Nov 6, 2003

Filed:

Jan 27, 2003

Appl. No.:

10/351895

Inventors:

Yuqiang Wang - Cupertino CA, US
Susan Wright - Saratoga CA, US
James Larrick - Woodside CA, US

International Classification:

A61K031/4025
A61K031/4015

US Classification:

514/422000, 514/424000

Abstract:

Disclosed herein are novel compositions and methods for the treatment of cancer and other diseases. More particularly, the present invention provides compositions and methods for reversing the resistance and increasing the sensitivity of apoptosis-resistant cells to all forms of cancer therapies, such as radiation and chemotherapy, for the treatment of apoptosis-resistant cancers.

US Patent:

20040191843, Sep 30, 2004

Filed:

Feb 2, 2004

Appl. No.:

10/770668

Inventors:

Susan Wright - Saratoga CA, US
James Larrick - Woodside CA, US
David Wilson - Mountain View CA, US
Steffen Nock - Redwood City CA, US

Assignee:

Palo Alto Institute of Molecular Medicine

International Classification:

G01N033/574
A61K039/395

US Classification:

435/007230, 424/178100

Abstract:

The invention provides compositions comprising amino acid sequences that have cell killing activity, nucleic acid sequences encoding them, antibodies that specifically bind with them, and methods of using these compositions for increasing and/or reducing cell death, detecting cell death, diagnosing diseases associated with altered cell death, and methods for identifying test agents that alter cell death.

US Patent:

20070037739, Feb 15, 2007

Filed:

Feb 3, 2004

Appl. No.:

10/544241

Inventors:

Yuqiang Wang - Cupertino CA, US
James Larrick - Woodside CA, US
Susan Wright - Saratoga CA, US

Assignee:

Medlogics Device Corporation - Santa Rosa CA

International Classification:

A61K 38/17
A61K 31/7034
A61K 31/4745
A61K 31/05

US Classification:

514012000, 514035000, 514283000, 514044000, 514733000

Abstract:

At least one bioactive agent is locally delivered to a location where a stent is implanted within a lumen in a patient's body. The bioactive agent includes a: DNA minor groove binder (such as CC-1065 or Duocarmycin); apocynin; RGD peptide (such as RGDfV); stilbene compound (such as resveratrol); camptothecin; des-aspartate angiotensin I; or ADF; or an analog or derivative thereof; or a combination or blend thereof with at least one other bioactive agent. The bioactive agent is generally locally delivered, such as by elution from the stent. The compounds and methods are of particular benefit for treating or preventing atherosclerosis, stenosis, restenosis, smooth muscle cell proliferation, occlusive disease, or other abnormal lumenal cellular proliferation condition.

US Patent:

59521899, Sep 14, 1999

Filed:

Mar 26, 1997

Appl. No.:

8/825193

Inventors:

Susan C. Wright - Saratoga CA
James W. Larrick - Woodside CA

Assignee:

Panorama Research, Inc. - Mountain View CA

International Classification:

C12Q 137
C12N 964

US Classification:

435 23

Abstract:

A method is disclosed for assaying for inhibitors of a 24 kDa cytoplasmic protease associated with apoptosis. The protease has a defined amino acid composition, activity against the elastase-like substrate MAAVP, and induces DNA fragmentation associated with apoptosis in isolated U937 cell target nuclei.

US Patent:

58439374, Dec 1, 1998

Filed:

May 23, 1996

Appl. No.:

8/652883

Inventors:

Yuqiang Wang - Mountain View CA
Susan C. Wright - Saratoga CA
James W. Larrick - Woodside CA

Assignee:

Panorama Research, Inc. - Mountain View CA

International Classification:

A61K 3140
A61K 31545
C07D48704
C07D50122

US Classification:

514202

Abstract:

The present invention relates to novel DNA alkylating agents and the prodrugs of these agents which are useful as antitumor agents and DNA labelling agents. The compounds are hydroxy dihydrobenzindole oligopeptides and prodrugs thereof wherein the monomeric constituents are derived from monocyclic or bicyclic heterocyclic aromatic residues.

US Patent:

56058268, Feb 25, 1997

Filed:

Jun 10, 1994

Appl. No.:

8/259752

Inventors:

Susan C. Wright - Saratoga CA
James W. Larrick - Woodside CA

Assignee:

Panorama Research, Inc. - Mountain View CA

International Classification:

C12N 964
C12N 950
C07K 122

US Classification:

435226

Abstract:

An apoptosis-associated protease having a relative mass of 24 kilodaltons and a defined amino acid composition is disclosed, together with a method for its purification from a cytoplasmic extract of mammalian cells treated with an apoptosis-inducing agent, such as tumor necrosis factor-. alpha. or UV irradiation, that comprises affinity chromatography with the serine protease inhibitor DK120 followed by heparin-sepharose chromatography. The protease has activity against the elastase-like substrate MAAPV and is capable of inducing apoptosis in isolated U937 cell target nuclei.